By: itellthetruthny
08 Jul 2004, 11:33 AM EDT
Msg. 159968 of 160097
Jump to msg. #  
A friend of mine has been taking AVR118 for 4 months straight now. His viral load due to Hep C was 1.1 million. It is now down to 53,700. He also has R/A since he was a young boy, he is now 39, and has tried every available medicine to help him and nothing has worked. His new blood work up shows his R/A is in complete remission and he has the proof from his blood tests. His doctor who approved him taking AVR118 and getting the drug through the compassionate use program approved by the FDA, from Canada, is very pleased and surprised about the results.
More doctors need to find out about AVR118 and it's wonderfull effects on people suffering with diseases that currently have no FDA approved available treatments that work as well as AVR118.

 
By: Ourobouros
08 Jul 2004, 11:42 AM EDT
Msg. 159969 of 160097
(This msg. is a reply to 159968 by itellthetruthny.)
Jump to msg. #  
As a contrary note, I was involved with a patient with hep c and she went with two rounds of AVR118 - before discontinuing it because of getting no response from the drug.

What I am trying to point out is that with every great report, there may be another with just the opposite result.

Meaning that anecdotal stories MAY sound good, but in the end they are totally worthless without any kind of double blinded testing.

Which is exactly where ADVR is right now, lots of good stories and such - but totally without any documented scientific evidence that the stuff works.

(Voluntary Disclosure: ST Rating- Strong Sell; LT Rating- Strong Sell)

 
By: lovingitall0
08 Jul 2004, 12:14 PM EDT
Msg. 159970 of 160097
(This msg. is a reply to 159968 by itellthetruthny.)
Jump to msg. #  
itellthetruthny: Thanks for posting something most welcomed here as opposed to the nonsense of the mindless one and his mindless cohorts.

It's always great to hear of these success stories with
Reticulose/AVR118.

Best of luck and continued good health to you and your friend.

Luv
 
By: DIAMONDring
08 Jul 2004, 12:25 PM EDT
Msg. 159971 of 160097
Jump to msg. #  
PLEASE heard MY FRIEND STUFF for 20 years PROOF IS THE PPS IS AT .11 END OF STORY!!!!!!!!!!

 
By: itellthetruthny
08 Jul 2004, 12:40 PM EDT
Msg. 159972 of 160097
(This msg. is a reply to 159971 by DIAMONDring.)
Jump to msg. #  
The PPS is not the issue hear. The issue is "that AVR118 is a powerfull new compound that I have seen work on various patients...from MS, R/A, Cancer patients, reversal of the inflamatory response of the immune system in pre-surgical procedures as well as other medical problems. The proof will come...give the new CEO the time and AVR118 will be a household name...My mother always told me, "if you have nothing nice to say, don't say it"..

(Voluntary Disclosure: LT Rating- Strong Buy)

 
By: lovingitall0
08 Jul 2004, 12:44 PM EDT
Msg. 159973 of 160097
(This msg. is a reply to 159971 by DIAMONDring.)
Jump to msg. #  
Diamond: The low PPS is a thorn in everyone's back.
Yet, there are success stories that we all know of.

I hope you'll never have a need for Reticulose/AVR118 until the PPS is where you and we all want it to be.

Until that day comes, feel some compassion for those that are using it with great results.

Luv
 
By: lovingitall0
08 Jul 2004, 12:46 PM EDT
Msg. 159975 of 160097
Jump to msg. #  
Vaccine scandal revives cancer fears, vaccines contaminated with a monkey virus linked to cancer

08 Jul 2004

Many millions more people than previously thought might have been given polio vaccine contaminated with a monkey virus linked to cancer.

It has been known since 1960 that early doses of polio vaccine were widely contaminated with simian virus 40, or SV40, which infects macaque monkeys. Tens of millions of people in the US and an unknown number in other countries, including the UK, Australia and the former Soviet Union, may have been exposed prior to 1963.

The contamination occurred because the kidney cells the vaccine virus was grown in came from monkeys infected with SV40. Health officials say the problem was eliminated after 1963.

Now Michele Carbone of Loyola University Medical Center in Chicago has announced results that suggest the Soviet polio vaccine was contaminated after 1963, possibly until the early 1980s. "Is there infectious virus? The short answer is, yes," Carbone told the Vaccine Cell Substrate Conference 2004 in Rockville, Maryland, last week.

The vaccine was almost certainly used throughout the Soviet bloc and probably exported to China, Japan and several countries in Africa. That means hundreds of millions could have been exposed to SV40 after 1963. The consequences of exposure to the virus (which is not related to HIV in any way) are unclear.

There is evidence is that some of the people given contaminated vaccines were infected by SV40, and that such infections might lead to the development of certain rare types of cancer many years down the line.

But the link with cancer has neither been proved, nor shown to be false (see "Does SV40 contamination matter?"). "There are two scenarios," says Philip Minor of the National Institute for Biological Standards and Control in the UK.

"One is that it doesn't matter. The other is that it does." Minor found three samples of the Soviet oral polio vaccine from the late 1960s in the NIBSC's freezers, the only samples known to survive from this time. In 1999, he found they tested positive for SV40, whereas British samples from this period did not.

"But we did not draw any broad conclusions," Minor says. Now Carbone has carried out further tests. He has confirmed the presence of SV40 in the Soviet vaccine samples using three separate tests. In two of the samples, he also showed that the SV40 remained infectious. In the third sample, there was no infectious poliovirus either, an indication that the sample of the live vaccine may have degraded. Yet the production process was supposed to ensure that if any SV40 was present, it would be neutralised.

When Carbone tested the Soviet neutralisation method, which relied on magnesium chloride, he found it was only 95 per cent effective. Because of this, he believes the Soviet vaccine could have remained contaminated until the early 1980s.

In 1981, the Soviet Union switched to a polio vaccine seed provided by the World Health Organization that was free from any SV40 contamination. Carbone, the first to publish evidence of a link between SV40 and the deadly lung cancer mesothelioma (New Scientist, 21 May 1994, p 4), will not discuss his results further until they have been published.

Officials from the US Food and Drug Administration who attended the conference also declined to comment, as the FDA is a defendant in lawsuits alleging that the SV40-contaminated polio vaccine used in the US has caused cancer cases. Hilary Koprowski of Jefferson University in Philadelphia, who created one of the first polio vaccines, says he is not surprised that the magnesium chloride preparation did not work.

"Nothing inactivates something 100 per cent," he said. "I would believe there were still remnants [of SV40] left." The contamination of the Soviet vaccine highlights the need for safer methods of growing viruses for vaccines, Koprowski says, something he is trying to tackle by using plant cells.

The US stopped using fresh monkey kidneys for polio vaccine in 2000. But the vaccine is still made in this way in several other countries. "I would say that it suggests that [old] vaccines made in different countries should be examined for possible contamination," says Janet Butel of Baylor University College of Medicine in Houston, a leading SV40 expert.

"In any epidemiological studies where they're comparing exposed versus non-exposed, if in fact there was any contaminated vaccine used after 1963, the control group wouldn't be a control group." Konstantin Chumakov of the FDA Center for Biologics Evaluation and Research, says that Carbone's findings leave many unanswered questions.

For example, he said it is not clear from the labelling of the samples found at the NIBSC exactly when they were used in the Soviet Union or for how long. Chumakov, whose father was director of the Soviet Institute of Poliomyelitis Research during the time of the contamination, says he was told that at one point the Soviet Union was supplying more than 100 countries with its vaccine.

He travelled to Moscow in April to try to learn more about the production and testing of the Soviet vaccine. But he found no more vaccine samples from that era, and very little surviving documentation about specific batches and why they might have been contaminated. "It's hard to explain how it happened," he says, "but it obviously did."

Author: Debbie Bookchin

This article appears in New Scientist issue: 10 July 2004







 
By: r909
08 Jul 2004, 02:19 PM EDT
Msg. 159993 of 160097
(This msg. is a reply to 159938 by lovingitall0.)
Jump to msg. #  
isn't it a shame there is no news like this for the advr crew... many companies have caught up or surpassed advr because the could not get their head out of their assessss.

well lets hope that oneday soon we will see something as nice as the reports you post



thanks for the info
rick
 
By: r909
08 Jul 2004, 02:21 PM EDT
Msg. 159994 of 160097
(This msg. is a reply to 159944 by kevtod.)
Jump to msg. #  
i remember when it was 1996 was going to be a big year short lived though then they hired Dr. hammer the stock price down hershman.

 
Advertisements
By: r909
08 Jul 2004, 02:22 PM EDT
Msg. 159995 of 160097
(This msg. is a reply to 159945 by mind31.)
Jump to msg. #  
come on now that is too soon maybe 2017? float 16billion shares price .09 still exec options exerciseable at .001 10billion opt outstanding

 
By: r909
08 Jul 2004, 02:26 PM EDT
Msg. 159996 of 160097
(This msg. is a reply to 159969 by Ourobouros.)
Jump to msg. #  
my cousin used it because of hep c in conjuction with intferon and got healthy but he stopped after 2 months out of money....
- - - - -
View Replies
 
By: lovingitall0
08 Jul 2004, 02:32 PM EDT
Msg. 159997 of 160097
(This msg. is a reply to 159993 by r909.)
Jump to msg. #  
r909, Thanks, and: YES, we've waited so very long and AVR118 deserves to be on Front Page by now.

It hurts seeing other companies there when we aren't.

I hope, as I've always said, that we can all live long enough to see it, feel it, enjoy it, for all the longing, all the loyalty, and all and belief that so many of us had and still do.

Good Luck to you. Good Luck to all of us.

Luv
 
By: mind31
08 Jul 2004, 02:56 PM EDT
Msg. 160005 of 160097
(This msg. is a reply to 159996 by r909.)
Jump to msg. #  
r909, your example demonstrates the falacy of anecdotal reports - if your cousin was taking 118 AND interferon, which was responsible for the improvement? Hard to say huh? Also was he taking anything else?

 
By: kevtod
08 Jul 2004, 03:21 PM EDT
Msg. 160027 of 160098
(This msg. is a reply to 159996 by r909.)
Jump to msg. #  
rick- "but he stopped after 2 months out of money...."

Yea, Sounds like real "compassionate use" to me.....That was the first lie that came out the post from "itellthetruthny"s first post here......

BTW- I was only trying to cheer up Diamond with the "2005 will be a big year" thing....lol....

IAG.....-kevtod
 
By: itellthetruthny
08 Jul 2004, 03:46 PM EDT
Msg. 160041 of 160099
Jump to msg. #  
The FDA allows patients with the proper forms signed by a member of the medical community (a doctor) and a signed letter from the patient explaining the indication for the use of AVR118. A copy of your drivers license and a release statement also must be included. The cost of each box (25 ampules)is $200 plus fedx. The FDA allows the drug to come into this country from Canada as long as it is made outside the USA. The drug that comes from Canada was made in Freeport Bahamas. The compassionate use just means the FDA allows the drug to come into this country for individual application with the proper forms.
 
By: mind31
08 Jul 2004, 04:41 PM EDT
Msg. 160053 of 160099
(This msg. is a reply to 160051 by itellthetruthny.)
Jump to msg. #  
tellthetruth, Hep-C is a very complex disease- different genotypes of the virus and differing progressions in different patients. Did your friend stop using alcohol, drugs or medications metabolized by the liver. Did your friend make any lifestyle changes? Also six months after treatment with interferon and ribavirin (the usual cocktail) seems to be the crucial follow up date. From WebMD-

"Treatment effectiveness
In a recent large study of combination treatments, 54% of people overall who took a high dose of peginterferon alfa-2b with ribavirin had no virus in their blood 6 months after treatment, compared with 47% of people who took either a lower-dose peginterferon with ribavirin or standard interferon with ribavirin; people infected with the genotype 1 strain of the virus had a response of 42% with the higher-dose peginterferon and ribavirin, compared with 34% of people taking a lower-dose peginterferon and ribavirin and 33% of people taking standard interferon and ribavirin.

A study of another form of peginterferon (peginterferon alfa-2a) plus ribavirin found that it lowered the virus to an undetectable level (and maintained that response 6 months after treatment) in 56% of people compared with 44% who took interferon alfa-2b plus ribavirin."
 
By: lovingitall0
08 Jul 2004, 06:18 PM EDT
Msg. 160069 of 160099
(This msg. is a reply to 160068 by 4titudinous.)
Jump to msg. #  
StockGate: Bank of America, SG Cowen Made 'Bets' Against Companies, Says WSJ

Jul 8, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Bank of America's (BAC) Banc of America Securities LLC and Societe Generale's (SCGLF) SG Cowen Securities Corp. are being investigated for possible insider trading relative to PIPE transactions related to hedge funds, according to the Dow Jones' (DJ) Wall Street Journal.

"The U.S. Securities and Exchange Commission is looking at whether hedge funds, tipped off to Pipe deals by brokers, made bets against the companies' stocks before the deals were consumated and publicly announced," according to the WSJ.

Usually such "bets" are in the form of short sales, sometimes "naked short sales."

WSJ said BayStar Capital, a California hedge fund, is specifically being probed.

In a June 23 release, the SEC stated it has put into place Rule 202(T), which establishes procedures to allow the Commission to temporarily suspend the operation of the current "tick" test in Rule 10a-1, and any short sale price test of any exchange or national securities association, for specified securities.

Through a separate order, the Commission will suspend, on a pilot basis for a period of one-year, the tick test provision of paragraph (a) of Rule 10a-1, and any short sale price test of any exchange or national securities association, for approximately one-third of stocks in the Russell 3000 index.

The order also will suspend, on a pilot basis for a period of one year, the tick test provision of paragraph (a) of Rule 10a-1 for short sales executed in any security included in the Russell 1000 index after 4:15 p.m. Eastern, and all other securities after the close of the consolidated tape, and until the open of the consolidated tape the next day.

The pilot will commence on January 3, 2005 to permit broker-dealers and self-regulatory organizations to make the necessary programming adjustments.

The Commission deferred consideration of the proposal to replace the current "tick" test of Rule 10a-1 with a new uniform bid test. The Commission could reconsider any further action on these proposals after the completion of the pilot.

Rule 203, which will incorporate current Rule 10a-2 and will create a uniform Commission rule requiring broker-dealers, prior to effecting short sales in all equity securities, to "locate" securities available for borrowing.

There will be limited exceptions from the locate requirement, including for short sales by registered market makers in connection with bona-fide market making.

Rule 203 also imposes additional requirements on designated "threshold securities." Rule 203 defines a threshold security to mean an equity security for which there is an aggregate fail to deliver position for five consecutive settlement days at a registered clearing agency of 10,000 shares or more and that is equal to at least 0.5% of the issue's total shares outstanding.

Where a clearing agency participant has a fail to deliver position in threshold securities that persists for ten consecutive days after settlement, the participant must take action to close out the position. Until the position is closed out, the participant, and any broker-dealer for which it clears transactions, may not effect further short sales in the particular threshold security without borrowing or entering into a bona fide arrangement to borrow the security.

Rule 203 will become effective 30 days after publication with a compliance date of January 3, 2005, to permit firms to make programming and procedural adjustments.

Rule 200, which among other things, will redesignate current Rule 3b-3 with some modifications to define ownership and aggregation of securities positions, and include a requirement to mark all sell orders in all equity securities. Rule 200 will become effective 30 days after publication.

The Commission also adopted amendments to Rule 105 of Regulation M to remove the current shelf offering exception, and issued interpretive guidance addressing sham transactions designed to evade the rule.

The amendment applies to short sales effected within five days prior to the pricing of a shelf offering. Such short sales may not be covered with offering securities purchased from an underwriter or other broker-dealer participating in the offering.

The Rule 105 amendments will be effective 30 days after publication in the Federal Register, and the interpretive guidance will be effective upon such publication.

Opponents of naked short selling were, however, quick to denounce the provision that allows market makers an exemption, and many market observers said that the SEC should provide a public list of companies that fall into the "threshold security" category.

"The SEC claims that the number of companies involved in this 'threshold security' category is 4% of all publicly traded companies. If in fact it is that small the process is certainly manageable," said the website InvestigatetheSEC.com at http://www.investigatethesec.com . "It is also the right of every issuer, in protecting their business and their investors to know the status of their stock trading."

Some were discussing whether the SEC can keep such information private under the Freedom of Information Act.

Recently observers were surprised to find a comment letter submitted to the SEC by Mike Alexander, Senior VP of Charles Schwab, that admits outright that brokerages regularly ignore rules and regulations, saying it is not rules that need to be written; it is changes in behavior that is needed.

The comments were directed towards proposed changes in the U.S. settlement system, but could easily apply to other regulations as well.

"Improvements in the U.S. settlement system will only be truly achieved if and when regulations are rationalized to ensure that all market participants are held accountable for compliance. For example, the industry has struggled with the issue of institutional trade affirmation for quite some time now. While the benefits to the clearance and settlement system are self-evident, Buy-Side firms and Custodian banks have been resistant to make those changes that provide for same-day trade confirmation / affirmation and assurance of trade settlement," said Alexander.

"Schwab opposes the notion that securities intermediaries such as broker-dealers be required to police compliance," he stated. "The NYSE and other SROs have had trade affirmation rules on their books for some time. However, such rules have not been effective in changing the behavior

of Buy-Side firms or their custodians; nor do the rules provide assurance that the affirmed trade will settle.

"Recognition of this fact is evidence that changes to the settlement cycle not only require overhauling systems, but also changing behavior. We believe that only by holding all market

participants directly accountable for making required affirmations will the necessary changes to behavior," he stated at http://www.sec.gov/rules/concept/s71304/charlesschwab061604.pdf .

The marketplace is already upset over promises by the Berlin Stock Exchange, since broken, that it would delist any company upon request.

"Please understand that cessation of trading in the shares of XRAYMEDIA Inc. (XRYM) is not possible," the exchange told one such requester.

It's not just U.S. companies such as Whistler Investments (WHIS), Sonoran Energy (SNRN), Celsion Corporation (CLN), and eLinear Inc. (ELU) or Israeli companies that have had serious concerns about their unannounced and unathrorized listings on the Berlin-Bremen Stock Exchange.

Apparently, some 150 British companies are protesting the same fate.

A number of UK-listed companies have demanded a London Stock Exchange investigation after they found that their shares are being traded.

Meanwhile, Whistler, Sonoran and eLinear have announced they have successfully secured their delistings, and the U.S. Securities and Exchange Commission has rescheduled its open hearing to consider the adoption of amendments to Regulation Sho to July 8 at 9:30 a.m. The announcement is at http://www.sec.gov/news/digest/dig061504.txt .

According to the London Money Telegraph, "several companies believe the market for their shares has been distorted and that they have fallen in value after trading started on the Berlin-Bremen exchange.

"Some smaller companies, whose shares are lightly traded in London, fear the Berlin market has been used by speculators to short-sell their shares."

The Telegraph said the number of companies are thought to be as high as 150, including even "larger companies" such as Matalan (OTC: MATNF) and Halfords.

Mladen Ninkov, the chairman of Aim-listed Griffin Mining (OTC: GFNMF), was quoted as saying: "We were put on the Berlin market without our knowledge by a German broker and now we've got about 8m shares out in a short sale. It is horrifying - that is about 4 per cent of the company and it is forcing the price down."

A spokesman for the London Stock Exchange said: "If there is evidence of market abuse we would refer that on to the appropriate authorities."

Whistler said that according to its transfer agent records, "we have 5,504,680 shares held by DTC, but the ADP broker search indicates of 6,217,458 shares being reported by broker/dealers as being held on behalf of their customers, indicating a short position of more than 700,000 shares. A summary report can be viewed at http://www.whistlerinvestments.com/shorts.html .

"We have therefore commenced work with DTC for a formal review of the reported excessive broker/dealer holdings of our stock so that we can conduct our corporate affairs properly in view of our planned stockholders meeting and other upcoming corporate matters. We again advise our stockholders make sure that they receive delivery of any shares that they purchase, and also that their stock is not being borrowed without authorization.

Holly Roseberry, President of Whistler Investments, states "We intend to get to the bottom of the excessive short position and bring stability back into the trading of our stock. We're happy to say that we have 5,133 stockholders and we expect all our stockholders to benefit from the shorters having to cover their short positions."

FinancialWire has reported on the disclosure that "Dateline," the investigatory TV program aired by General Electric's (GE) NBC unit, has purportedly been preparing a blockbuster expose of "Stockgate" (see separate story at http://www.financialwire.net).

It is not known if "Dateline" has uncovered continuing underworld connections to the scandal, but FinancialWire reported that Dateline may be pointing a large finger of conflict at the U.S. Securities and Exchange Commission itself, which reportedly receives a slice of every transaction fee as part of its budget. According to court filings supported by the O'Quinn/Christian legal network, almost $1 billion annually is received by the Depository Trust and Clearing Corp. for its "Stock Borrow Program," which the lawsuits claim is just a fancy name for counterfeiting, as the DTCC purportedly lends out many multiples of the actual certificates in the float. Apparently the SEC receives a transaction fee for each transaction facilitated by these loans of non-existent certificates, which could knock a hole in its budget should the revenues from the practice be halted.

The North American Securities Administrators Association, comprised of state and Canadian regulators, has pointedly told the SEC that either it must rethink its cozy DTCC relationship, or it hints, some of its more aggressive state practitioners (think Eliot Spitzer) may do the rethinking for the SEC.

Naked short selling is worrisome for hundreds of small U.S. companies, including those recently asking to be delisted from the Berlin Stock Exchange, such as Golden Phoenix Minerals, Inc. (GPXM), Nannaco, Inc. (NNCO), 5G Wireless Communications, Inc. (FGWC), CyberAds, Inc. (CYAD), Provectus Pharmaceuticals, Inc. (PVCT), House of Brussels Chocolates (HBSL), InforMedix, Inc. (IFMX), Tissera, Inc. (TSSR), Americana Publishing, Inc. (APBH), Celsion Corporation (CLN), ChampionLyte Holdings, Inc. (CPLY), Pickups Plus, Inc. (PUPS), China Wireless Communications Inc. (CWLC), CareDecision Corp. (CDED), Titan General Holdings, Inc. (TTGH), IPVoice Communications, Inc. (IPVO), Whistler Investments (WHIS), WARP Technology Holdings, Inc. (WRPT), BGR Corp. (OTCBB: BGRR), ICOA, Inc., (ICOA), DICUT, INC. (OTCBB: DCUTE), NHC Communications Inc. (NHC), Stratus Services Group, Inc. (SERV), Golden Phoenix Minerals, Inc. (GPXM).

Berliner Freiverkehr (Aktien) AG has been singled out as the broker and market maker that has been "listing" the companies. It is suspected that one broker, RA Angsar Limprecht, is involved in all if not most of the listings.

Small public companies are squeezed not only by hedge funds, naked short sellers, overseas listers such as the Berlin Stock Exchange, and the out-of-control "Stock Borrow Program" run by the governance-conflict-laden Depository Trust and Clearing Corporation, but to the amazement of the industry, as often and not by their own regulators.

A new staff recommendation by Annette Nazareth, director of the division of market regulation at the U.S. Securities and Exchange Commission to "outlaw" ownership of paper certificates at the same time the Depository Trust and Clearing Corporation is under intense scrutiny for alleged electronic counterfeiting has begun hitting the small public company markets, company executives, shareholders and manipulative short-selling opponents like the proverbial ton of bricks.

A Dow Jones (DJ) article by Judith Burns sparked the uproar, as the inextricably intertwined web of connections between the SEC and the DTC, which is sagging from the weight of conflicted governance by representatives from a rollcall of industry heavyweights, including NASD, which owns NASDAQ (NDAQ), the New York Stock Exchange, Goldman Sachs (GS) and Lehman Brothers (LEH), to name only a few.

The rule proposal would bar stock transfer agents from handling shares that carry any limitations on transfer. Control over stock certificates is one of the ways that small companies have combated illegal naked short sellers. Burns quoted Nazareth as saying that these companies' "self-help" efforts "aren't helping U.S. markets overall." Nazareth was quoted as saying restrictions on stocks are "a significant step backwards" in the "move from paper stock certificates to automated computerized trading."

Nazareth said that abusive "naked" short selling has been a problem "in some cases," but that is "best dealt with by a pending SEC proposal," presumably Regulation SHO.

SEC Commissioner William Donaldson purportedly publicly refused to answer any questions from the NASD about the timing of the Commission's consideration of the Regulation at a conference where he was simultaneously proposing early reforms of the mutual fund scandals. The Dow Jones said, however, that Robert Colby, SEC deputy market regulation division director, predicted the SEC will take that to a vote in early June.

The Dow Jones report noted that "naked short-selling occurs when sellers don't buy shares to replace those they borrowed, a manipulative practice that can drive a company's stock price sharply lower.

The stock certiticate plan has been put to a 30-day comment periodl Then the SEC would have to vote to adopt it. If adopted, Colby was quoted as saying that regulators might "sue firms that seek to impose restrictions on stock transfers."

The recent lawsuit filed by Nanopierce Technologies (NPCT) alleges that the Depository Trust and Clearing Corp. has a lot of reasons, almost one billion of them a year, to keep illegal naked short selling in operation. It was the shot across the bow by the legendary Houston law firms of Christian, Smith, Wukoson and Jewell, and OQuinn, Laminack and Pirtle, whose notches already include environmental targets, the breast implant industry and the tobacco industry, all brought to their knees.

In comments to the U.S. Securities and Exchange Commission, C. Austin Burrell, who is providing litigation support and research for the law firms, said that StockGate is more massive than anyone may have imagined. "Illegal Naked Short Selling has stripped hundreds of billions, if not TRILLIONS, of dollars from American investors," and have resulted in over 7,000 public companies having been "shorted out of existence over the past six years." Burrell said some experts believe as much as $1 trillion to $3 trillion has been lost to this practice.

He stated that the restrictions on short selling were deliberately put into the Securities Acts of 1933 and 1934 because of the first-hand evidence then available that the "sheer scale of the crashes was a direct result of intentional manipulation of US markets through abusive short selling by a massive conspiracy."

Burrell noted that the 65-lawyer team presided over by lead lawyers Wes Christian and John O'Quinn has uncovered more than 1,200 hedge fund and offshore accounts working through more than 150 broker-dealers and market makers in a joint cooperative effort to strip small and medium size public companies of their value.

Recently the NASD and U.S. Securities and Exchange Commission approved an interim naked short-selling band-aid, requiring U.S. brokers to make an "affirmative determination" that short-sellers, even foreign short-sellers, mostly Canadian, can find certificates to cover before processing the order.

Last year, many besieged public companies sought refuge from the manipulation by seeking to exit the DTC, but on July 8, 2003, the SEC stated "the issues surrounding naked short selling are not germane to the manner in which DTC operates as a depository registered as a clearing agency. Decisions to engage in such transactions are made by parties other than DTC. DTC does not allow its participants to establish short positions resulting from their failure to deliver securities at settlement. While the Commission appreciates commenters' concerns about manipulative activity, those concerns must be addressed by other means."

The Nanopierce lawsuit, said to be the first of many out of the box, emphatically suggests otherwise. According to lawyer Christian, et.al., the DTC is at the very heart of the problem, and has almost a billion dollars a year at stake in keeping the problem.

The Depository Trust Company (DTC) is a member of the U.S. Federal Reserve System, a limited-purpose trust company under New York State banking law and a registered clearing agency with the SEC. The depository supposedly brings efficiency to the securities industry by retaining custody of some 2 million securities issues, effectively "dematerializing" most of them so that they exist only as electronic files rather than as countless pieces of paper. The depository also provides the services necessary for the maintenance of the securities it has in "custody."

According to the suit, the DTCC has an enormous pecuniary and conflicted interest in the entire short selling scandal through the huge income stream they were realizing from it every day. They have made literally billions of dollars lending individual real shares, in most cases over and over, getting a fee each time they made a journal entry in the "Stock Borrow Program."

The Stock Borrow Program was purportedly set up to facilitate expedited clearance of stock trades. Somewhere along the line, the DTCC became aware that if it could lend a single share an unlimited number of times, it could collect a fee each time, according to Burrell. "There are numerous cases of a single share being lent ten or many more times," giving rise to the complaint that the DTCC has been electronically counterfeiting just as was done via printed certificates before the Crash.

"Such re-hypothecation has in effect made the potential 'float' in a single company's shares virtually unlimited and the term 'float' meaningless. Shares could be electronically created/counterfeited/kited without a registration statement being filed, and without the underlying company having any knowledge such shares are being sold or even in existence." Burrell said the Christian/O'Quinn lawsuits will seek to show that the "counterfeiting/creation of unregistered shares is a specific violation of the Securities Act of 1933, barring the 'Sale of Unregistered Securities'."

While the Nanopierce lawsuit has been filed at the state level, another companion lawsuit just heading to the courts on behalf of Exotics.com (EXII) will be argued at the Federal level.

Nanopierce's suit in the 2nd Judicial District Court in Nevada, is Case No. CV04-01079, alleges that the DTC's "stock borrow program" was "purportedly created to address SHORT TERM delivery failures," but that the "end result of the program has been to create tens of millions of unissued and unregistered shares to be traded in the public market," and in some instances resulting in "two or more shareholders who purchase shares in separate transactions to own the same shares."

The complaint alleges that the DTC has a colossal disincentive to stop the "stock borrow" program, booking revenues from services of $425,416,000 and similarly, the NSCC deriving revenues of $293,133,000.

Further, the suit alleges that "open positions" resulting from this activity at the close of business on December 31, 2003, "approximated $3,025,467,000" due to NSCC, and $2,303,717,000 due by NSCC, and unsettled positions of $721,750,000 for securities borrowed through the NSCC's "Stock Borrow Program."

Nanopierce claims that DTCC and NSCC have joined in a "scheme" to "manipulate downward the price of the affected securities, thereby reducing the market value of the open fail to deliver positions." The suit also claims that the defendants have permitted sellers to maintain open fail to deliver positions of tens of millions of shares for periods of a year and even longer.

It quotes the National Association of Security Dealers as admitting that "concerns have been raised by members, issuers, investors and other interested parties about potentially abusive short selling activities occurring in the marketplace. In particular, naked short selling, or selling short without borrowing securities to make delivery, can result in long term failures to deliver, including aggregate failures to deliver that exceed the total float of a security. NASD believes such extended failures to deliver can have a negative effect on the market. Among other things, by not having to deliver securities, naked short sellers can take on larger short positions than would otherwise be permissible, which can facilitate manipulative activity."

Nanopierce claims that it had "relied on material misrepresentations and omissions by DTC and NSCC in trading its shares in the stock market "without knowledge of Defendants' fraud-on-the market through statements they made about the clearing and settlement services they provided." Further, it claims that the Defendants acted with "scienter" since they had a major financial financial motivation to falsely represent their services, which Nanopierce claims are also anticompetitive.

The largely unregulated DTC has become something of a defacto Czar presiding over the entire U.S. markets system, wielding more day-to-day influence and control than the SEC, the NASD and NASDAQ combined. And, as the SEC's July 8 ruling indicates, its monopoly over the electronic trading system appears even to be protected.

The Depository Trust and Clearing Corp.'s two preferred shareholders are the New York Stock Exchange and the NASD, a regulatory agency that also owns the NASDAQ (NDAQ) and the embattled American Stock Exchange! Regulators, regulate thyself?

In an era when corporate governance is the primary interest for the SEC and state regulators, the DTCC is hardly a role model. Its 21 directors represent a virtual litany of conflict:

They include Bradley Abelow, Managing Director, Goldman Sachs (GS); Jonathan E. Beyman, Chief Information Officer, Lehman Brothers (LEH); Frank J. Bisignano, Chief Administrative Officer and Senior Executive Vice President, Citigroup / Solomon Smith Barney's Corporate Investment Bank (C); Michael C. Bodson, Managing Director, Morgan Stanley (MWD); Gary Bullock, Global Head of Logistics, Infrastructure, UBS Investment Bank (UBS); Stephen P. Casper, Managing Director and Chief Operating Officer, Fischer Francis Trees & Watts, Inc.; Jill M. Considine,Chairman, President & Chief Executive Officer, The Depository Trust & Clearing Corporation (DTCC);

Also, Paul F. Costello, President, Business Services Group, Wachovia Securities (WB); John W. Cummings, Senior Vice President & Head of Global Technology & Services, Merrill Lynch & Co. (MER); Donald F. Donahue, Chief Operating Officer, The Depository Trust & Clearing Corporation (DTCC); Norman Eaker, General Partner, Edward Jones; George Hrabovsky, President, Alliance Global Investors Service; Catherine R. Kinney, President and Co-Chief Operating Officer, New York Stock Exchange; Thomas J. McCrossan, Executive Vice President, State Street Corporation (STT); Eileen K. Murray, Managing Director, Credit Suisse First Boston (CSR); James P. Palermo, Vice Chairman, Mellon Financial Corporation (MEL); Thomas J. Perna, Senior Executive Vice President, Financial Companies Services Sector of The Bank of New York (BNY); Ronald Purpora, Chief Executive Officer, Garban LLC; Douglas Shulman, President, Regulatory Services and Operations, NASD; and Thompson M. Swayne, Executive Vice President, JPMorgan Chase (JPM).

In their comments to the SEC regarding Regulation SHO in January, the 50 state regulators, through their association, the North American Association of Securities Administrators (NASAA) issued what many consider to be a strong warning that if the DTC is not dealt with in the final regulations, state regulators such as New York State Attorney General Eliot Spitzer may step to the plate.

In what many considered to have been explosive comments, Ralph Lambiase, NASAA president and Director of the Connecticut Division of Securities, warned "NASAA urges the Commission to reconsider its stance regarding the role of the Depository Trust and Clearing Corporation (the DTC). As a threshold matter, NASAA believes that the Commission should explicitly prohibit the DTC from lending more shares of a security than it actually holds. The ability of the overall proposed rule would be severely impared unless the Commission undertakes to implement such a prohibition."

As the Nanopierce lawsuit reveals, those were indeed strong words, meddling as it did, in a substantial revenues base for the DTCC.

Recently, leading market makers and brokers named in various lawsuits and other actions, including FleetBoston (NYSE: FBF), Goldman, Sachs & Co. (GS), H. Myerson & Co., Inc. (NASDAQ: MHMY), Olde / H&R Block (HRB), Charles Schwab (SCH), Toronto-Dominion's (TD), TD Waterhouse Group and vFinance, Inc. (VFIN). A.G. Edwards, Inc. (AGE), Ameritrade Holding Corp. (AMTD), Deutsche Bank AG (DB), and ETrade Group, Inc. (ET), were forced to comply with new short-selling market regulations imposed by the NASD after the SEC had "sat on" the NASD request to plug material loopholes for almost 2-1/2 years.

"The new rules expand the scope of the affirmative determination requirements to include orders received from broker/dealers that are not members of NASD ("non-member broker/dealers").

The new rule is on the web at http://www.nasdr.com/2610_2004.asp#04-03

The rule itself, while welcomed by small companies and their shareholders in the U.S., nevertheless raised an outcry because the NASD's request to put it into effect had set on a shelf at the SEC since 2001.

The scandal has embroiled hundreds of companies and dozens of brokers and marketmakers, in a web of internaitional intrigue, manipulative short-selling and cross-border acctions and denials.

Comments on Regulation SHO ended January 5, and may be viewed at http://www.sec.gov/rules/proposed/s72303.shtml .

Some 122 companies, including 13 brokers, such as FleetBoston (NYSE: FBF), Goldman, Sachs & Co. (GS), H. Myerson & Co., Inc. (NASDAQ: MHMY), Olde / H&R Block (HRB), Charles Schwab (SCH), Toronto-Dominion's (TD), TD Waterhouse Group and vFinance, Inc. (VFIN). A.G. Edwards, Inc. (AGE), Ameritrade Holding Corp. (AMTD), Deutsche Bank AG (DB), and ETrade Group, Inc. (ET), have been embroiled for over a year in a raging controversy

The remaining 109 companies among the 122 named to date have issued press releases or been named in the media as having been victimized, or as taking various actions, either alone or in concert with other companies, to oppose manipulative trading in the form of illegal naked short selling. The actions have ranged from lawsuits to withdrawals and threatened withdrawals from the electronic trading system managed by the Depository Trust & Clearing Corp., to withdrawals from toxic financings, to the issuance of dividends or name changes designed to squeeze manipulators, to joining associations or networks or to contacting regulatory authorities to provide documentation of abuses or otherwise complain.

The complete list of those 108 companies include Advanced Viral Research Corp. (ADVR), AdZone Research, Inc. (ADZR), Amazon Natural Treasures (OTC: ANTD), America's Senior Financial Services (OTCBB: AMSE), American Ammunition, Inc. (AAMI), AngelCiti Entertainment (OTCBB: AGLC), ATSI Communications, Inc. (ATSC), Federal Agricultural Mortgage / Farmer Mac (AGM) Allied Capital (ALD), American Motorcycle (OTC: AMCYV), American International Industries (AMIN), Ameri-Dream (OTC: AMDR), Adirondack Pure Springs Mt. Water Co. (OTCBB: APSW), ATSI Communications,Inc. (ATSC) Bluebook International (BBIC), Blue Industries (OTCBB: BLIIV), Bentley Communications (OTCBB: BTLY), BIFS Technologies Corporation (BIFT), Biocurex (BOCX). Broadleaf Capital Partners, Inc. (BDLF), Chattem, Inc. (CHTT), Critical Home Care (CCLH), Composite Holdings (COHIA), CyberDigital, Inc. (CYBD). Diamond International Group (OTCBB: DMND), Dobson Communications Corp. (DCEL), Eagle Tech Communications (EATC), Edgetech Services (EDGH);

Also, Endovasc Ltd. (EVSC), Enviro-Energy Corporation (ENGY), Environmental Products & Technologies (OTC: EPTC), Environmental Solutions Worldwide, Inc. (ESWW), EPIXTAR Corp. (EPXR), eResearchTechnologies, Inc. (ERES), Flight Safety Technologies (OTCBB: FLST), Freddie Mac (FRE), FreeStar Technologies (OTCBB: FSRCE), Front Porch Digital,

Inc. (FPDI), Geotec Thermal Generators, Inc. (GETC), Genesis Intermedia (GENI), GeneMax Corp. (GMXX), Global Explorations Inc (GXXL), Global Path (OTCBB: GBPI), GloTech Industries, Inc. (OTCBB: GTHI), Green Dolphin Systems (OTCBB: GLDS), Group Management (OTCBB: GPMT), Hop-On (HPON), H-Quotient, Inc., (HQNT), Hyperdynamics Corp. (HYPD), International Biochem (IBCL), Intergold Corp. (OTCBB: IGCO), International Broadcasting Corporation (IBCS), InternetStudios, Inc. (ISTO), ITIS Holdings (ITHH), Investco Corp. (IVCO), Lair Holdings (LAIR), Lifeline BioTechnologies Inc. (LBTT), Life Energy & Technology (LETH), MBIA (MBI);

Also, MegaMania Interactive (MNIA), MetaSource Group, Inc. (MTSR),Midastrade.com (MIDS), Make Your Move (OTCBB: MKMV), Medinah Minerals (MDMN), MSM Jewelry Corp. (OTC: MSMC), Nanopierce Technologies, Inc. (NPCT), Nutra Pharmaceutical (NPHC), Nutek (OTCBB: NUTK), Navigator Ventures (NVGV), Orbit E-Commerce, Inc. (OECI), Pitts & Spitts (OTC: PSPP), Sales OnLine Direct (OTCBB: PAID), Pacel Corp. (OTCBB: PACC), PayStar Corporation (PYST),Petrogen Corp. (PTGC), Pinnacle Business Management (OTC: PCBM), Premier Development & Investment, Inc. (PDVN), PrimeHoldings.com, Inc. (PRIM), Phlo Corporation (PHLC), Resourcing Solutions (RESG), Reed Holdings (OTC: RDHC), Rocky Mountain Energy Corp. (OTCBB: RMECE), RTIN Holdings (OTCBB: RTNHE), Saflink Corp. (SFLK), Safe Travel Care (OTCBB: SFTVV), Sedona Corp. (SDNA);

Also, Sionix Corp. (SINX), Sonoran Energy (SNRN), Starmax Technologies (SMXIF), Storage Suites America (SSUA), Suncomm Technologies (OTC: STEH), Sports Resorts International (SPRI), Technology Logistics (TLOS), Swiss Medica, Inc. (SWME), Ten Stix, Inc. (TNTI), Tidelands Oil (TIDE), Titan Construction (TTCS), Trezac Corp. (OTCBB: TRZAV), Universal Express, Inc. (USXP), Valesc Holdings, Inc. (OTCBB: VLSHV), Vega Atlantic (OTCBB: VGAC), Viragen (VRA), Viragen International (VGNI), Vista Continental Corporation, (VICC), Viva International (VIVI), Vtex Energy (OTCBB: VXENE) and Wizzard Software (WIZD), WorldTradeShow.com (WTSW) and Y3K Secure Enterprise Software, Inc. (OTCBB: YTHK).

Earlier in 2003, the SEC fined Rhino Advisors, Inc., $1 million for its representation of Amro International in the financing and manipulation of Sedona Corp. Amro, also known as AMRO, was registered in Panama, a secretive offshore haven, but was not named in the SEC settlement. Another 60 public companies may have been manipulated by the fined Rhino Advisors and its indicted principals, or its funding apparatus, Amro.

These include:

All American Food Group Inc (AAFGQ), Amanda Co Inc (AMNA), Antra Holdings (RECD), Aquis Communications Group Inc (OTCBB: AQUIS), Avanir Pharmaceuticals (AVN), Bionutrics Inc (BNRX), Brilliant Digital Entertainment Inc (AMEX: BDE), Bravo! Foods International Corp. (OTCBB: BRVOE), Butler National Corp (BUTL),Calypte Biomedical Corp (CYPT), Chemtrak Inc/DE (CMTR), Clicknsettle Com Inc (CLIK), Corporate Vision Inc (OTC: CVIA), Crown Laboratories Inc/DE (CLWB), Dental Medical Diagnostic Systems Inc (DMDS), Detour Media Group Inc (DTRM),

Also, Digital Privacy Inc/DE (OTC: DGPV), Senior Services Inc (DISS), International Inc (DYNX), Endovasc Ltd Inc (EVSC), Esynch Corp/CA (OTCBB: ESYN), Focus Enhancements Inc (NASDAQ: FSCE), Frederick Brewing Co (FRBW), Greystone Digital Technology Inc (GSTN), Havana Republic Inc/FL (HVNR), Henley Healthcare Inc (HENL), Hollywood Media Corp (HOLL), Ibiz Technology Corp (IBZT), Diagnostic Systems Inc/FL (IMDS), Imaging Technologies (OTCBB: IMTO), Integrated Surgical Systems Inc (RDOC),

Also, Interferon Sciences Inc (IFSC), Interiors Inc (OTC: ITRNA), Laminaire Corp (THMZ), Medisys Technologies Inc (SCEP), Milestone Scientific Inc/NJ (MS), Nevada Manhattan Group Inc (NVMH), Innovations Inc (OTCBB: NTGE),Systems Group (OSYM), Pacific Systems Control Technology Inc (PFSY), Professional Transportation Group Ltd Inc (TRUC), Rnethealth Inc (RNTT),

Also, Sand Technology Inc (SNDT), Sedona Corp (SDNA), Silverado Foods Inc (SVFO), Stockgroup Information Systems (SWEB) Surgilight Inc (SRGL), Tasty Fries Inc (TFRY), Tech Laboratories Inc (TCHL), Teltran International Group Ltd (TLTG), Titan Motorcycle Co of America Inc (TMOTQ), Trans Energy Inc (TSRG), Motorcycle Co (UMCC), Universal Communication Systems Inc (UCSY), Medical Systems Inc (UMSI), Vianet Technologies Inc (VNTK),Viragen Inc (VRA), Webcatalyst Inc (WBCL), Worldwide Wireless Networks Inc (WWWNQ), and ZAP (ZAPZ).

Universal Express terminated its coverage in Investrend Research's unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following. Just prior to the termination, Investrend Research analyst Jeff Howlett had issued a "Speculative" rating on the company, a downgrade from the previous "Speculative Buy."

The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com

Investrend Research subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adheres to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the Association for Investment Management and Research (http://www.aimr.org).

The Dow Jones Newswires has stated that independent research has been growing in credibility over the past 18 months, specifically citing Investrend Research, and the New York Times has reported a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."

Enrollment fees for Institutional coverage were $23,400 per annum, and the fees were paid by the company for two years. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms.

Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
================
By: 4titudinous
08 Jul 2004, 06:12 PM EDT Msg. 160068 of 160068

http://www.investors.com/breakingnews.asp?journalid=22028791&brk=1




 
By: gatorbak
08 Jul 2004, 07:09 PM EDT
Msg. 160079 of 160099
Jump to msg. #  
I Strongly Suggest that Anyone Thats Unhappy With AVR118 or ADVR , Dump and Buy some other PENNY STOCK , ..Us Longs get Tired of the WHINING.....PLEASE,. Do yourselves IMO

(Voluntary Disclosure: Position- Long; LT Rating- Strong Buy)

 
By: r909
09 Jul 2004, 12:59 AM EDT
Msg. 160098 of 160099
(This msg. is a reply to 160005 by mind31.)
Jump to msg. #  
he started on the i and was getting really sick and depressed i got him the juice and within 3 weeks his counts where moving toward a vital state no longer depressed was able to work full 8 - 10 hour days.. but when the money ran out he could not afford it he was shooting for 1 year but the cost of the interferon and the juice he didn't have enough. so back at work saving the bucks but he still does not feel as sick as he did. he is off both now and yes he still has hep c ... he is saving his bucks to last 1 year on the juice.